CoChat

Tie2-FGFR1 interaction induces adaptive PI3K inhibitor resistance by upregulating Aurora A/PLK1/CDK1 signaling in glioblastoma.

Published version of a preprint

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Abstract

PI3K-targeting therapy represents one of the most sought-after therapies for glioblastoma (GBM). Several small-molecule inhibitors have been evaluated in clinical trials, however, the emergence of resistance limits treatment potential. Here, we generated a patient-derived glioma sphere-forming cell (GSC) xenograft model resistant to the PI3K-specific inhibitor BKM-120. Integrated RNA sequencing and high-throughput drug screening revealed that the Aurora A kinase (Aurora A)/Polo-like kinase 1 (PLK1)/cyclin-dependent kinase 1 (CDK1) signaling pathway was the main driver of PI3K inhibitor resistance in the resistant xenografts. Aurora kinase was upregulated and pCDK1 was downregulated in resistant tumors from both xenografts and tumor tissues from patients treated with the PI3K inhibitor. Mechanistically, the tyrosine kinase receptor Tie2 physically interacted with FGFR1, promoting STAT3 phosphorylation and binding to the AURKA promoter, which increased Aurora A expression in resistant GSCs. Concurrent inhibition of Aurora A and PI3K signaling overcame PI3K inhibitor-induced resistance. This study offers a proof of concept to target PI3K and the collateral-activated pathway to improve GBM therapy. SIGNIFICANCE: These findings provide novel insights into the mechanisms of PI3K inhibitor resistance in glioblastoma.

Overview

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-19-0325

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 40 references

Cited by

See all 28

Metadata

Authors
Li, X., Martinez-Ledesma, E., Zhang, C., Gao, F., Zheng, S., Ding, J., Wu, S., Nguyen, N., Clifford, S. C., Wen, P. Y., Ligon, K. L., Yung, W. K. A., & Koul, D.
Affiliations
  • The University of Texas MD Anderson Cancer Center (US)
  • 1Brain Tumor Center, Departments of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Texas A&M University (US)
  • Brigham and Women's Hospital (US)
Corresponding author
Koul, Dimpy
Venue
Cancer Research
Published
2019-10-01
Volume
79
Issue
19
Pages
5088-5101
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2968054305
Cited by
27
References
40
Citations by year
2026: 3 · 2025: 3 · 2024: 2 · 2023: 6 · 2022: 5 · 2021: 7 · 2020: 1
FWCI
1.79
Type
journal article
Language
en
Open access
closed
Locations
  • Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • The National Brain Tumor Society
  • The National Foundation for Cancer Research
  • SPORE (P50CA127001)
Topics
  • Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › FOXO transcription factor regulation
Keywords
glioblastoma, PI3K inhibitor resistance, Tie2, FGFR1, AURKA, PLK1, CDK1, STAT3 phosphorylation, glioma stem cells, drug resistance, combination therapy
MeSH terms
Polo-Like Kinase 1, Animals, Glioblastoma, Humans, Male, Mice, Nude, Proto-Oncogene Proteins, Signal Transduction, Up-Regulation, CDC2 Protein Kinase, Protein Serine-Threonine Kinases, Cell Cycle Proteins, Drug Resistance, Neoplasm, Phosphatidylinositol 3-Kinases, Receptor, TIE-2, Protein Kinase Inhibitors, Mice, Receptor, Fibroblast Growth Factor, Type 1, Aurora Kinase A, Heterografts

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tie2-FGFR1 interaction induces adaptive PI3K inhibitor resistance by upregulating Aurora A/PLK1/CDK1 signaling in glioblastoma. https://app.cochat.ai/papers/10.1158/0008-5472.can-19-0325
The paper
Li, X., Martinez-Ledesma, E., Zhang, C., Gao, F., Zheng, S., Ding, J., Wu, S., Nguyen, N., Clifford, S. C., Wen, P. Y., Ligon, K. L., Yung, W. K. A., & Koul, D. (2019). Tie2-FGFR1 interaction induces adaptive PI3K inhibitor resistance by upregulating Aurora A/PLK1/CDK1 signaling in glioblastoma. Cancer Research. https://doi.org/10.1158/0008-5472.can-19-0325

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.